Siranalen

Pregabalin

Neuropathic pain including diabetic peripheral neuropathy & post-herpetic neuralgia in adults. Generalised anxiety disorder (GAD) in adults. Adjunctive therapy of partial seizures, w/ or w/o secondary generalisation in adults. Management of fibromyalgia.

Dose range: 150-600 mg/day given in 2 or 3 divided doses. Neuropathic pain Initially 150 mg/day, may be increased to 300 mg/day after 3-7 days interval. Max: 600 mg/day after an additional 7-day interval. Epilepsy Initially 150 mg/day, may be increased to 300 mg/day after 1 wk. Max: 600 mg/day after an additional wk. GAD Initially 150 mg/day, may be increased to 300 mg/day after 1 wk. Following an additional wk, may be increased to 450 mg/day. Max: 600 mg/day after an additional wk. Fibromyalgia 300-450 mg/day. Initially 75 mg bd, may be increased to 150 mg bd w/in 1 wk. Max: 225 mg bd. Renal impairment: CrCl ≥60 mL/min Initially 150 mg/day, bd or tds. Max: 600 mg/day. CrCl ≥30-<60 mL/min Initially 75 mg/day, bd or tds. Max: 300 mg/day. CrCl ≥15-<30 mL/min Initially 25-50 mg/day, once daily or bd. Max: 150 mg/day. CrCl <15 mL/min Initially 25 mg/day, once daily. Max: 75 mg/day. Following haemodialysis Supplementary dose: 25 mg/day as a single dose. Max: 100 mg/day.

May be taken with or without food.

Hypersensitivity.

Hypersensitivity reactions including angioedema. Discontinue immediately if angioedema symptoms (eg, facial, perioral or upper airway swelling) occur. Diabetic patients who gain wt may need to adjust hypoglycaemic medications. Dizziness & somnolence. Transient visual blurring & other visual acuity changes. W/drawal symptoms (eg, insomnia, headache, nausea, anxiety, hyperhidrosis, diarrhoea, flu syndrome, nervousness, depression, pain, sweating & dizziness) after discontinuation of short- & long-term treatment. Evaluate patients for history of drug abuse & observe for signs of misuse/abuse. Patients w/ severe CHF. Elevated creatine kinase levels. Discontinue if myopathy is diagnosed or suspected. Monitor for signs of suicidal ideation & behaviours. Patients w/ rare hereditary problems of galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption. Co-administration w/ CNS depressants including opioids. Monitor patients for symptoms of resp depression & sedation in patients w/ underlying resp impairment or co-prescribed w/ CNS depressants. May affect ability to drive & use machines. Women of child-bearing potential must use effective contraception. Pregnancy & lactation. Childn <12 yr. Elderly >65 yr.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, attention disturbance, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, drunk & abnormal feeling, fatigue; increased wt.

May potentiate ethanol & lorazepam effects. Additive in the cognitive & gross motor function impairment caused by oxycodone. Potential risk of resp failure & coma w/ other CNS depressants. Lower GIT function (eg, intestinal obstruction, paralytic ileus, constipation) may be reduced w/ opioid analgesics. Possible resp failure, coma & deaths in patients concomitantly taking other CNS depressants, including substance abusers.

Anticonvulsants

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.